Paull K, Hodes L, Simon R M
J Natl Cancer Inst. 1986 Jun;76(6):1137-42.
Well over 100,000 compounds have been screened by the National Cancer Institute (NCI) in mouse leukemia P388 in the search for new leads toward antineoplastic agents. The protocol for screening requires confirmation testing of compounds showing initial activity. By activity criteria being varied for initial and confirmation testing, it is possible to improve the efficiency of screening. The experimental variability of P388 screening was first determined by analysis of outcomes from 90 tests on each of 21 compounds of varied activity. By application of these results to NCI P388 data for 31,428 compounds adequately tested on a daily times five schedule, the consequences of using different activity thresholds were estimated. The results here may apply to those of other similar large-scale screening programs.
美国国立癌症研究所（NCI）已在小鼠白血病P388模型中对超过100,000种化合物进行了筛选，以寻找抗肿瘤药物的新线索。筛选方案要求对显示出初步活性的化合物进行确证试验。通过改变初步试验和确证试验的活性标准，可以提高筛选效率。P388筛选的实验变异性首先通过对21种活性各异的化合物各自进行90次试验的结果分析来确定。将这些结果应用于按每日五次计划充分测试的31,428种化合物的NCI P388数据，估算了使用不同活性阈值的后果。此处的结果可能适用于其他类似的大规模筛选项目。
